Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints

IF 4.9 Q1 CHEMISTRY, MEDICINAL

ACS Pharmacology and Translational Science Pub Date : 2025-02-21 DOI:10.1021/acsptsci.4c0072710.1021/acsptsci.4c00727

Julian Guercetti, Marc Alorda, Luciano Sappia, Roger Galve, Macarena Duran-Corbera, Daniel Pulido, Ginevra Berardi, Miriam Royo, Alicia Lacoma, José Muñoz, Eduardo Padilla, Silvia Castañeda, Elena Sendra, Juan P. Horcajada, Agustín Gutierrez-Galvez, Santiago Marco, J.-Pablo Salvador* and M.-Pilar Marco,

{"title":"Immuno-μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints","authors":"Julian Guercetti, Marc Alorda, Luciano Sappia, Roger Galve, Macarena Duran-Corbera, Daniel Pulido, Ginevra Berardi, Miriam Royo, Alicia Lacoma, José Muñoz, Eduardo Padilla, Silvia Castañeda, Elena Sendra, Juan P. Horcajada, Agustín Gutierrez-Galvez, Santiago Marco, J.-Pablo Salvador* and M.-Pilar Marco, ","doi":"10.1021/acsptsci.4c0072710.1021/acsptsci.4c00727","DOIUrl":null,"url":null,"abstract":"A multiplexed microarray chip (Immuno-μSARS2) aiming at providing information on the prognosis of the COVID-19 has been developed. The diagnostic technology records information related to the profile of the immunological response of patients infected by the SARS-CoV-2 virus. The diagnostic technology delivers information on the avidity of the sera against 28 different peptide epitopes and 7 proteins printed on a 25 mm2 area of a glass slide. The peptide epitopes (12–15 mer) derived from structural proteins (Spike and Nucleocapsid) have been rationally designed, synthesized, and used to develop Immuno-μSARS2 as a multiplexed and high-throughput fluorescent microarray platform. The analysis of 755 human serum samples (321 from PCR+ patients; 288 from PCR– patients; 115 from prepandemic individuals and classified as hospitalized, admitted to intensive-care unit (ICU), and exitus) from three independent cohorts has shown that the chips perform with a 98% specificity and 91% sensitivity identifying RT-PCR+ patients. Computational analysis utilized to correlate the immunological signatures of the samples analyzed indicate significant prediction rates against exitus conditions with 82% accuracy, ICU admissions with 80% accuracy, and 73% accuracy over hospitalization requirement compared to asymptomatic patients’ fingerprints. The miniaturized microarray chip allows simultaneous determination of 96 samples (24 samples/slide) in 90 min and requires only 10 μL of sera. The diagnostic approach presented for the first time here could have a great value in assisting clinicians in decision-making based on the information provided by the Immuno-μSARS2 regarding progression of the disease and could be easily implemented in diagnostics of other infectious diseases.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 3","pages":"871–884 871–884"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00727","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.4c00727","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

A multiplexed microarray chip (Immuno-μSARS2) aiming at providing information on the prognosis of the COVID-19 has been developed. The diagnostic technology records information related to the profile of the immunological response of patients infected by the SARS-CoV-2 virus. The diagnostic technology delivers information on the avidity of the sera against 28 different peptide epitopes and 7 proteins printed on a 25 mm² area of a glass slide. The peptide epitopes (12–15 mer) derived from structural proteins (Spike and Nucleocapsid) have been rationally designed, synthesized, and used to develop Immuno-μSARS2 as a multiplexed and high-throughput fluorescent microarray platform. The analysis of 755 human serum samples (321 from PCR+ patients; 288 from PCR– patients; 115 from prepandemic individuals and classified as hospitalized, admitted to intensive-care unit (ICU), and exitus) from three independent cohorts has shown that the chips perform with a 98% specificity and 91% sensitivity identifying RT-PCR+ patients. Computational analysis utilized to correlate the immunological signatures of the samples analyzed indicate significant prediction rates against exitus conditions with 82% accuracy, ICU admissions with 80% accuracy, and 73% accuracy over hospitalization requirement compared to asymptomatic patients’ fingerprints. The miniaturized microarray chip allows simultaneous determination of 96 samples (24 samples/slide) in 90 min and requires only 10 μL of sera. The diagnostic approach presented for the first time here could have a great value in assisting clinicians in decision-making based on the information provided by the Immuno-μSARS2 regarding progression of the disease and could be easily implemented in diagnostics of other infectious diseases.

查看原文本刊更多论文

免疫μ sars2芯片：基于免疫指纹图谱的多肽芯片评估COVID-19预后

研制了一种多路复用微阵列芯片（Immuno-μSARS2），旨在提供新冠肺炎的预后信息。该诊断技术记录了与SARS-CoV-2病毒感染患者免疫反应谱相关的信息。该诊断技术可提供血清对28种不同肽表位和7种蛋白质的亲和力信息，这些信息被打印在25平方毫米的玻璃载玻片上。合理设计合成了结构蛋白（Spike和Nucleocapsid）衍生的肽表位（12-15 mer），并用于开发Immuno-μSARS2作为多路复用和高通量荧光微阵列平台。755份人血清样本分析(PCR阳性患者321份；PCR患者288例；来自三个独立队列的115名大流行前个体，被分类为住院、入住重症监护病房（ICU）和出院，结果表明，该芯片识别RT-PCR+患者的特异性为98%，灵敏度为91%。与无症状患者的指纹相比，用于关联所分析样本的免疫特征的计算分析表明，对出院情况的预测准确率为82%，对ICU入院的预测准确率为80%，对住院要求的预测准确率为73%。微型化微阵列芯片可在90分钟内同时检测96个样品（24个样品/载玻片），仅需10 μL血清。本文首次提出的诊断方法对临床医生根据免疫μ sars2提供的疾病进展信息进行决策具有重要价值，并且可以很容易地应用于其他传染病的诊断。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)

CiteScore

10.00

自引率

3.30%

发文量

133

期刊介绍： ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.